India, June 15 -- Celldex (CLDX), a biopharmaceutical company, on Sunday reported positive data from the Phase 1 trial for CDX-622, a bispecific antibody developed to target chronic inflammation by neutralizing alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells through stem cell factor (SCF) starvation. Results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 annual meeting.
The first-in-human Phase 1 trial was a randomized, double-blind, placebo-controlled, dose-escalation study to determine pharmacokinetic and pharmacodynamic activity of CDX-622 over several doses.
The combined neutralization of SCF and TSLP by CDX-622 was studied in the trial, and results show that a rapid, dose-d...